Literature DB >> 9204654

The management of diabetes in patients with advanced cancer.

J Poulson1.   

Abstract

The management of diabetes mellitus is often complicated in patients with advanced cancer. Anorexia and nausea or vomiting make caloric intake erratic. The use of diabetogenic medications such as glucocorticoids can produce profound hyperglycemia. Many malignant tumors cause derangement in intermediary metabolism and abnormal glucose tolerance in up to one-third of patients. Both hyperglycemia and hypoglycemia impair the quality of life of dying patients. Swings in blood sugar should be avoided wherever possible, but aggressive blood sugar monitoring also impairs quality of life. This paper discusses issues in the management of diabetes in patients with advanced cancer and suggests guidelines for maintaining glycemic control without excessive interventions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9204654     DOI: 10.1016/s0885-3924(96)00326-0

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  5 in total

1.  Development of Gendine-Coated Cannula for Continuous Subcutaneous Insulin Infusion for Extended Use.

Authors:  Mohamed A Jamal; Kumait Garoge; Joel S Rosenblatt; Ray Y Hachem; Issam I Raad
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

2.  Impact of high glucose on metastasis of colon cancer cells.

Authors:  Cheng-Yao Lin; Chih-Hui Lee; Chien-Cheng Huang; Song-Tay Lee; How-Ran Guo; Shih-Bin Su
Journal:  World J Gastroenterol       Date:  2015-02-21       Impact factor: 5.742

3.  Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma.

Authors:  Manal M Hassan; Steven A Curley; Donghui Li; Ahmed Kaseb; Marta Davila; Eddie K Abdalla; Milind Javle; Dalia M Moghazy; Richard D Lozano; James L Abbruzzese; Jean-Nicolas Vauthey
Journal:  Cancer       Date:  2010-04-15       Impact factor: 6.860

4.  Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3.6 million people.

Authors:  Charlotte Andersson; Allan Vaag; Christian Selmer; Michelle Schmiegelow; Rikke Sørensen; Jesper Lindhardsen; Gunnar H Gislason; Lars Køber; Christian Torp-Pedersen
Journal:  BMJ Open       Date:  2012-06-08       Impact factor: 2.692

5.  A Pilot Study Evaluating Steroid-Induced Diabetes after Antiemetic Dexamethasone Therapy in Chemotherapy-Treated Cancer Patients.

Authors:  Yusook Jeong; Hye Sook Han; Hyo Duk Lee; Jiyoul Yang; Jiwon Jeong; Moon Ki Choi; Jihyun Kwon; Hyun-Jung Jeon; Tae-Keun Oh; Ki Hyeong Lee; Seung Taik Kim
Journal:  Cancer Res Treat       Date:  2016-02-29       Impact factor: 4.679

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.